Last reviewed · How we verify
NCT06657131: [18F]PSMA-1007
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
trial in Prostate Cancer After a Radical Treatment in 250 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | Heinrich-Heine University, Duesseldorf |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 November 2024 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 November 2028 |
| Sites | 1 location across Germany |
Conditions studied
- Prostate Cancer After a Radical Treatment — all drugs for Prostate Cancer After a Radical Treatment →
- Biochemical Recurrence of Malignant Neoplasm of Prostate — all drugs for Biochemical Recurrence of Malignant Neoplasm of Prostate →
- Biochemical Persistence of Prostate Cancer — all drugs for Biochemical Persistence of Prostate Cancer →
Sponsor
Heinrich-Heine University, Duesseldorf
Who can join
18 and older, male only, with Prostate Cancer After a Radical Treatment or Biochemical Recurrence of Malignant Neoplasm of Prostate. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Biphasic contrast-enhanced [<sup>18</sup>F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer.
Mamlins E, Novruzov E, Watabe T, Mori Y, et al · · 2025 · cited 1× · PMID 40445472 · DOI 10.1186/s13550-025-01252-4
Verify or expand the search:
- PubMed search for NCT06657131
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Heinrich-Heine University, Duesseldorf trials
Trials by the same sponsor.
- NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
- NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
- NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
- NCT07254663 — GEL & MEDication Dysphagia · recruiting
- NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06657131 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06657131.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing